Sera Prognostics, Inc. (NASDAQ: SERA) is a Healthcare company (Medical - Devices) with a market capitalization of $78M. The Maz Rating grades it against the other companies in its sector.
Sera Prognostics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.00, Sera Prognostics, Inc. trades at 784.1x sales and 1.9x book value. Over the last twelve months it generated about $98969 of revenue and a net loss of $27M. It runs a gross margin of -103.1%, an operating margin of -38755.2% and a net margin of -34866.7%. It shows return on equity of -52.5%, return on invested capital of -66.8% and a free cash flow yield of -37.4%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 1.88. Over the past 52 weeks the share price ranged from $1.56 to $3.85, with a beta of 1.14.
Sera Prognostics, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 4 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Sera Prognostics, Inc. (SERA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 70.5% / 30% · Interest income / Revenue 1883.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 42.7% / 33% · Receivables / Mkt Cap (36m) 0.02% / 49% · Interest income / Revenue 1883.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 42.7% / 33.33% · Receivables / Mkt Cap (24m) 0.02% / 33.33% · Interest income / Revenue 1883.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 48.9% / 33.33% · Receivables / Avg Assets (4Q) 0.01% / 33.33% · Interest income / Revenue 1883.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 55.1% / 33.33% · (Cash+Recv) / Total Assets 55.1% / 33.33% · Interest income / Revenue 1883.3% / 5% | Fail |
No. As of September 2026, Sera Prognostics, Inc. (SERA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Sera Prognostics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 1883.3% of each dividend: Sera Prognostics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.